/

IFRX

InflaRx N.V.After hours

1.55−0.04 −2.52%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.55 0.00%

Open

1.59

Prev close

1.59

Day range

1.541.61

52-week range

0.79802.95

Volume

367.13K0.47×

Mkt cap

228.42M

P/E ttm

—

Fwd P/E

-4.00

EPS ttm

-0.5800

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−47.44%

Price Chart

Yahoo Finance · delayed

IFRXOct 13, 2026O 1.59H 1.61L 1.54C 1.55−0.04 (−2.52%)Vol 367.13K

SMA 501.98
SMA 2001.61

1Y change +12.32% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IFRX InflaRx N.V. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.90%
1 month: −25.84%
3 months: −22.89%
6 months: +35.96%
Year to date: +53.47%
1 year: +24.00%

Valuation & ownership

Market cap: 228.42M
Enterprise value: 76.63M
P/E (ttm): —
Forward P/E: -4.00
PEG ratio: —
Price / book: 1.39
Price / sales (ttm): -22613.68
EV / EBITDA: -2.15
EPS (ttm): -0.5800
EPS (forward): -0.3876
Beta (5y monthly): 2.61
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 147.37M
Float: 98.11M
Short % of float: 9.15%
Short ratio (days): 24.81
Held by insiders: 2.95%
Held by institutions: 70.39%
Avg volume (3m): 775.30K
50-day average: 1.98
200-day average: 1.60
52-week change: +24.00%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 29.8
vs 50-day SMA: −21.54%
vs 200-day SMA: −3.46%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.96%
Realised vol (20d, ann.): 43.6%
From 52-week high: −47.44%
From 52-week low: +94.24%

ANR

Analyst Consensus

9 analysts

Consensus

—

Mean target

7.65

+393.75% implied

Low 2.92Median 7.78High 13.61

Recommendation trend

Now8 / 1 / 0
1m ago7 / 1 / 0

DES

About InflaRx N.V.

Yahoo Finance profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Sector: Healthcare
Industry: Biotechnology
Employees: 65
Headquarters: Jena, Germany
Website: inflarx.de
Officers: Prof. Niels C. Riedemann M.D., Ph.D. Co-Founder, CEO & Executive Director

SEAS

Seasonality · IFRX

2017–2026 · monthly returns

Strongest month Apr +42.40%Weakest month Jun −17.44%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-12.7	4.3	-2.8	131.5	15.9	-6.7	-24.1	25.3	-15.5	-13.9			+53.5%
2025	-2.4	-42.3	-26.6	66.7	-52.8	-1.6	14.6	76.8	-16.2	9.0	-13.7	-19.8	−59.1%
2024	-0.6	9.9	-13.5	-11.0	4.4	21.7	-13.8	6.0	-3.8	1.3	58.7	0.4	+51.5%
2023	-30.0	-10.8	0.3	151.0	-14.0	6.4	-6.1	-5.7	-24.6	-43.3	-20.1	20.7	−47.4%
2022	-25.0	-25.5	-31.2	-7.7	-5.9	-8.8	89.0	-19.3	19.5	-1.5	0.0	19.2	−34.9%
2021	6.2	-22.3	-6.0	-2.6	-19.7	-2.6	-12.5	-1.2	0.8	63.7	18.2	-5.0	−5.4%
2020	-18.4	31.3	-9.9	85.1	24.8	-48.0	9.4	-12.4	-3.2	-10.3	8.1	21.8	+27.0%
2019	-9.8	13.0	2.0	22.0	-21.9	-91.2	-5.7	-4.7	-13.0	7.3	28.3	16.5	−89.1%
2018	14.3	8.9	10.5	35.7	-2.6	-15.4	-5.2	11.2	1.0	-6.2	-9.3	24.5	+73.6%
2017												-1.6	−1.6%

IFRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IFRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About InflaRx N.V.

Seasonality · IFRX

Insider Activity · IFRX

Congress Trades · IFRX

Investors Holding IFRX

Investors Holding IFRX

Congress Trades · IFRX

Insider Activity · IFRX

Seasonality · IFRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About InflaRx N.V.

Financial Snapshot

Earnings & Dividends

News